Homepage
Latest Videos
Latest Videos
Brightcove Home Latest Listing
Breast Cancer
Breast Cancer
Brightcove Cards Listing
Prostate Cancer
Brightcove Cards Listing
Multiple Myeloma
Multiple Myeloma
Brightcove Cards Listing
Popular on MedEnrich
Popular in No name
Myelodysplastic Syndromes14m 13s
ASH 2022 Update on Myelodysplastic Syndromes
ASH 2022 - Update on Myelodysplastic Syndromes
low risk mds
eln classification
low dose lenalidomide
viale -a
tags: azacitidine
venetoclax
1

ASH 2022 Update on Myelodysplastic Syndromes
Prostate Cancer45m 55s
Treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC)
Treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC)
metastatic hormone-sensitive prostate cancer (mhspc)
androgen deprivation therapy (adt)
chemotherapy
docetaxel
improved patient survival rates
1

Treatment intensification in metastatic...
Breast Cancer3m 56s
Duration of trastuzumab in patients with Her2 positive Metastatic Breast Cancer in prolonged remission
There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.
her2 positive mbc
prolonged remission
trastuzumab duration
1

Duration of trastuzumab in patients with Her2...
Myelodysplastic Syndromes7m 3s
Clinical Application of Web Based Tool for Improving MDS Diagnosis
Gradient Based Model based on 10 routinely used parameters (Age, Gender, Hb, WBC, MCV, Platelets, Neutrophils, Monocytes, Glucose, Creatinine) is now available to facilitate non-invasive diagnosis of MDS.
mds
non-invasive diagnosis
1

Clinical Application of Web Based Tool for...
Breast Cancer8m 50s
Immunotherapy of Early Breast Cancer
I-SPY2 clinical trial laid the foundation for Immunotherapy in Early Breast Cancer with Pembrolizumab added to Neoadjuvant Chemotherapy.
keynote -522
immunotherapy
early breast cancer
1

Immunotherapy of Early Breast Cancer
Oncology9m 34s
Case Based Learning in Cardio Oncology
Immunotherapy mediated cardiotoxicity like myocarditis & cardiovascular issues arising of cytokine release syndrome can become more common with increasing adoption of Immunotherapy in cancer treatment.
car-t cell therapy
cytokine release syndrome
immunotherapy mediated myocarditis
1

Case Based Learning in Cardio Oncology
Breast Cancer14m 46s
ESMO 2022 Breast Cancer Comprehensive Coverage
View comprehensive coverage of Breast Cancer from ESMO 2022
dose dense adjuvant chemotherapy
esmo
keynote -522
monarch -3 study
1

ESMO 2022 Breast Cancer Comprehensive Coverage
Critical Care10m 35s
Is it time to replace calcium based phosphate binder with non-calcium phosphate binders?
In this video, Dr. Floege talks about the supportive evidence available and guideline recommendations on the preferred use of non-calcium phosphate binders.
cac score
phosphate binders
sevelamer
lanthanum
sucroferric oxyhydroxide
kdigo guideline.
1

Is it time to replace calcium based phosphate...
Prostate Cancer6m 59s
Managing Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)
3 randomized clinical trials (SPRATAN- Apalutamide), (PROSPER -Enzalutamide) & (ARAMIS -Darolutamide) have shown consistent and almost similar benefit in Metastasis Free Survival in nmCRPC
nmcrpc
metastasis free survival
spartan
prosper & aramis clinical trial
1

Managing Nonmetastatic Castration-Resistant...
Myelodysplastic Syndromes2m 31s
Duration of treatment does it improve outcomes Hypomethylating agents in MD
Need to maximise the response to hypomethylating agents: Standard of care for high-risk Myelodysplastic Syndromes is Hypomethylating agents. Average time to response is about 3 months with either Azacytidine or Decitabine.
duration of treatment
hypomethylating agents
mds
1

Duration of treatment does it improve outcomes...
For Pharmacist
For Pharmacist
Brightcove Cards Listing
Webinars
Webinar Cards Listing
MedBytes
MedBytes
Medbytes Cards Listing
Login
To get access to full MedEnrich experience, please Sign in
Don’t have an account? Register Now